A lot of screening is done for STIs. In fact it is a common diagnostic test.
I understand we might see sales of the enteric pathogen test in Europe this year, which will be a nice step forward. Its also exciting the process for FDA approval has begun.
I agree this stock is under the radar. Bioshares haven't even covered it, virtually since the company listed. As I said previously there's a shift to molecular methods underway at present and we're really well placed.
Ann: GSS Launches Sexually Transmitted Infection (STI) Kit, page-8
Add GSS (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
67.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $155.4M | |||
| Open | High | Low | Value | Volume |
| 70.0¢ | 70.0¢ | 67.5¢ | $8.472K | 12.18K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 29814 | 67.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 69.5¢ | 900 | 1 |
View Market Depth
| Last trade - 11.38am 03/12/2024 (20 minute delay) ? |
| GSS (ASX) Chart |
